文献速递免疫规划职业卫生

澳大利亚医护人员百日咳加强免疫抗体应答观察研究

An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers.
PubMed 文献 · Vaccine · 2021-02-13

本研究比较了曾接种成人Tdap加强针(5-12年前)与首次接种Tdap的澳大利亚儿科医护人员在接种后1周、1月、1年的IgG应答。两组疫苗耐受良好,既往加强组基线IgG较高且PT抗体血清阳性率更高,接种后1月两组IgG均显著升高,既往加强组上升更快,1月至1年间PT和FHA抗体衰减相似,但首次接种组PRN抗体衰减更快。

要点

  • 既往Tdap加强者基线百日咳抗体水平及血清阳性率高于首次接种者
  • 两组接种后1月IgG均显著升高,既往加强组上升更迅速
  • 支持儿科医护人员至少每10年重复接种Tdap加强针

核心结论

  • 全细胞百日咳疫苗初始免疫的澳大利亚成人接种Tdap后免疫记忆可维持长达12年。
  • 无证据表明加强接种后百日咳免疫应答衰减更快。
  • 研究结果支持当前建议:儿科医护人员至少每10年重复接种Tdap加强针。

研究设计与样本

  • 观察性研究,比较既往接种过成人Tdap加强针(5-12年前)与首次接种Tdap的澳大利亚儿科医护人员。
  • 在接种后1周、1月、1年比较IgG应答。
  • 临床试验注册号:ACTRN12615001262594。

主要发现

  • 两组Tdap接种均耐受良好。
  • 既往加强组所有疫苗抗原的接种前IgG浓度显著更高。
  • 既往加强组PT-IgG血清阳性率(≥5 IU/mL)为69.5%(95%CI 59.5-79.5),首次接种组为45.2%(95%CI 32.8-57.5)。
  • 接种后1月两组IgG应答均显著升高;既往加强组上升更快,接种后1周PT-IgG几何平均倍数增长分别为3.6(95%CI 2.9-4.3)和2.6(95%CI 2.2-3.2)。
  • 接种后1月至1年间,PT和FHA特异性IgG衰减两组相似;PRN-IgG衰减首次接种组(GMC比值0.36;95%CI 0.31-0.42)快于既往加强组(GMC比值0.45;95%CI 0.39-0.50)。

关键数值与推荐

  • PT-IgG血清阳性阈值:≥5 IU/mL。
  • 破伤风毒素保护性IgG滴度阈值:≥0.1 IU/mL。
  • 白喉类毒素保护性IgG滴度阈值:≥0.1 IU/mL。
  • 推荐儿科医护人员至少每10年重复接种Tdap加强针。

临床怎么用

  • 儿科医护人员应至少每10年接种一次Tdap加强针以维持百日咳免疫。
  • 既往加强接种者再次接种后抗体上升更快,支持定期加强策略。
  • 需关注首次接种者PRN抗体衰减较快现象,但PT和FHA衰减与既往加强者相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult pertussis vaccination is increasingly recommended to control pertussis in the community. However, there is little data on the duration and kinetics of immunity to pertussis boosters in adults. We compared IgG responses to vaccination with a tetanus, low-dose diphtheria, low-dose acellular pertussis (Tdap) booster at 1 week, 1 month and 1 year post-vaccination in whole-cell (wP)-primed Australian paediatric healthcare workers who had received an adult Tdap booster 5-12 years previously, to those who received their first Tdap booster. Tdap vaccination was well tolerated in both groups. Previously boosted adults had significantly higher pre-vaccination IgG concentrations for all vaccine-antigens, and more were seropositive for pertussis toxin (PT)-specific IgG (≥ 5 IU/mL) (69.5%; 95% confidence interval (CI) 59.5-79.5) than adults in the naïve group (45.2%; 95% CI 32.8-57.5). Tdap vaccination significantly increased IgG responses 1 month post-vaccination in both groups. This increase was more rapid in previously boosted than in naïve adults, with geometric mean fold-increases in PT-IgG at 1 week post vaccination of 3.6 (95% CI 2.9-4.3) and 2.6 (95% CI 2.2-3.2), respectively. Antibody waning between 1 month and 1 year post-vaccination was similar between groups for IgG specific to PT and filamentous haemagglutinin (FHA), but was faster for IgG against pertactin (PRN) in the naïve group (GMC ratio 0.36; 95% CI 0.31-0.42) than the previously boosted group (GMC ratio 0.45; 95% CI 0.39-0.50). At baseline, all but one adult had protective IgG titres against tetanus toxin (TT) (≥ 0.1 IU/mL), and 75.6% in the previously boosted and 61.3% in the naïve group had protective IgG titres against diphtheria toxoid (DT) of ≥ 0.1 IU/mL. This study shows that pertussis immune memory is maintained up to 12 years after Tdap vaccination in wP-primed Australian adults. There was no evidence that pertussis immune responses waned faster after a booster dose. These findings support current recommendations of repeating Tdap booster vaccination in paediatric healthcare workers at least every 10 years. Clinical trials registry: ACTRN12615001262594.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McAlister SM, van den Biggelaar AHJ, Woodman TL, et al. An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers. Vaccine. 2021. PMID: 33589299. doi:10.1016/j.vaccine.2021.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。